AstraZeneca: COVID-19 trials
The registry lists 43 COVID-19 studies with AstraZeneca as lead sponsor. 1 are open to participants now and 17 have results posted.
Phase 1 10Phase 2 8Phase 3 9Phase 4 1No phase 18(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenRecruitingNCT05624450Phase 3
- Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19CompletedNCT06057064Phase 2Results posted
- Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)CompletedNCT05648110Phase 2/3Results posted
- A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19TerminatedNCT05375760Phase 2Results posted
- AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in PediatricsCompletedNCT05281601Phase 1Results posted
- A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese AdultsCompletedNCT05184062Phase 2Results posted
- A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised AdultsTerminatedNCT05057897Phase 4Results posted
- Phase II/III Study of AZD2816, for the Prevention of COVID-19 in AdultsCompletedNCT04973449Phase 2/3Results posted
- Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient AdultsCompletedNCT04723394Phase 3Results posted
- Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in AdultsCompletedNCT04625972Phase 3Results posted
- Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.CompletedNCT04625725Phase 3Results posted
- Study of AZD1222 for the Prevention of COVID-19 in JapanCompletedNCT04568031Phase 1/2Results posted
- Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in AdultsCompletedNCT04516746Phase 3Results posted
- AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19CompletedNCT04507256Phase 1Results posted
- Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19TerminatedNCT04497948Phase 1Results posted
- Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.CompletedNCT04380688Phase 2Results posted
- Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe PneumoniaTerminatedNCT04369469Phase 3Results posted
- Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.CompletedNCT04346199Phase 2Results posted
- An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in JapanCompletedNCT06156982
- A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19CompletedNCT06147063Phase 1
- Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult ParticipantsCompletedNCT05932641Phase 1
- Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in ChinaCompletedNCT05917951
- Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response StudyCompletedNCT05872958Phase 1
- eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health ServicesCompletedNCT05712096
- Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil StudyCompletedNCT05697705
- Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)CompletedNCT05687877
- eVusheld Assessment reaL wORld Effectiveness at UPMCCompletedNCT05667116
- eVusheld Assessment reaL wORld Effectiveness in the VA Health SystemCompletedNCT05663957
- eVusheld Assessment reaL wORld Effectiveness in DoD Health SystemCompletedNCT05569408
- A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese AdultsCompletedNCT05437289Phase 1
- Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council CountriesCompletedNCT05315323
- LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE StudyCompletedNCT05282017
- Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 VaccinesCompletedNCT05252442
- Epidemiology of Thrombotic Thrombocytopenia Syndrome in Integrated Health-care Database in EnglandCompletedNCT05222750
- EU Secondary Data Post-Authorisation Safety Study of AZD1222CompletedNCT05126992
- Oxford/AstraZeneca COVID-19 Vaccine Effectiveness in EnglandCompletedNCT05047822
- Phase I Double-blind, Placebo-controlled Study of AZD7442CompletedNCT04896541Phase 1
- Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222TerminatedNCT04877743
- COVID-19 Soliris Expanded Access ProtocolNo longer availableNCT04802083
- A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for RabeprazoleCompletedNCT04564040Phase 1
- AZD1222 Vaccine for the Prevention of COVID-19WithdrawnNCT04540393Phase 3
- An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19Status unknownNCT04527133Not applicable
- SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19No longer availableNCT04355494